Gonadotropin-releasing hormone agonist analog (nafarelin): a useful diagnostic agent for the distinction of constitutional growth delay from hypogonadotropic hypogonadism.

Kletter GB, Rolfes-Curl A, Goodpasture JC, Solish SB, Scott L, Henzl MR, Beitins IZ

Journal of pediatric endocrinology & metabolism : JPEM1 Jan 1996Cited by 7 (Europe PMC)

PMID8887129DOI10.1515/jpem.1996.9.1.9PepBankPUB-08887129

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone5

In this study, Nafarelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Nafarelin.

01HumanNot a test of Nafarelin aloneNon-randomized trialActivity measurement
In healthy men, diagnostic nafarelin produced significantly higher peak LH, FSH, and testosterone than GnRH (p < 0.001).
In plain wordsIn healthy men, peak LH, FSH, and testosterone were higher after diagnostic nafarelin than GnRH.
Peptide
Nafarelin
Outcome
IncreasePeak LH, FSH, and testosterone stimulation
Study
n = 20
Comparator
GnRH diagnostic test
Outcome group
Sex hormones and fertility · Endocrine and hormones
Source sentences
Summary
Peak stimulation of plasma LH, FSH and T released by nafarelin was significantly higher, and it took a longer time to reach the peak maximum, than after GnRH (p < 0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
In addition, 20 normal healthy men aged 21 yr to 50 yr received either nafarelin or GnRH followed two weeks later by the other test in order to compare the efficacy of each of these tests and to evaluate the optimal sampling times for the nafarelin test.
In this study, Nafarelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Nafarelin.
Report a problemFND-0888712901
02HumanNot a test of Nafarelin aloneNon-randomized trialActivity measurement
In healthy men, diagnostic nafarelin took longer to reach peak LH, FSH, and testosterone than GnRH (p < 0.001).
In plain wordsIn healthy men, LH, FSH, and testosterone peaked later after diagnostic nafarelin than GnRH.
Peptide
Nafarelin
Outcome
IncreaseTime to peak LH, FSH, and testosterone
Study
n = 20
Comparator
GnRH diagnostic test
Outcome group
Sex hormones and fertility · Endocrine and hormones
Source sentences
Summary
Peak stimulation of plasma LH, FSH and T released by nafarelin was significantly higher, and it took a longer time to reach the peak maximum, than after GnRH (p < 0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
In addition, 20 normal healthy men aged 21 yr to 50 yr received either nafarelin or GnRH followed two weeks later by the other test in order to compare the efficacy of each of these tests and to evaluate the optimal sampling times for the nafarelin test.
In this study, Nafarelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Nafarelin.
Report a problemFND-0888712902
03HumanNot a test of Nafarelin aloneObservational studyActivity measurement
After diagnostic nafarelin, peak LH was higher with constitutional growth delay than hypogonadotropic hypogonadism, 36.9 versus 7.0 IU/I (p < 0.001).
In plain wordsPeak LH after diagnostic nafarelin was higher with constitutional growth delay than hypogonadotropic hypogonadism.
Peptide
Nafarelin
Outcome
IncreasePeak LH diagnostic response by diagnosis
Study
n = 11
Comparator
Hypogonadotropic hypogonadism
Outcome group
Sex hormones and fertility · Endocrine and hormones
Measurements
Mean peak LH
36.9 IU/I
CGD
Peak LH dispersion
8.9 IU/I
CGD +/-
Mean peak LH
7 IU/I
HH
Peak LH dispersion
2 IU/I
HH +/-
P value
< 0.001
CGD vs HH
Source sentences
Summary
Peak LH responses to nafarelin were 36.9 +/- 8.9 IU/I for the CGD group, and 7.0 +/- 2.0 IU/I for the HH group (p < 0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
we evaluated six boys (mean age 15 yr 4 m) and five HH patients (mean age 20 yr 4 m).
Summary · context
Each of the patients had blood withdrawn every 15 min during 12 h overnight followed by a single s.c. injection of nafarelin (1 microgram(s)/kg up to 100 microgram(s)), except two HH patients who did not have an overnight study.
In this study, Nafarelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Nafarelin.
Report a problemFND-0888712903
04HumanNot a test of Nafarelin aloneObservational studyActivity measurement
After diagnostic nafarelin, peak FSH was higher with constitutional growth delay than hypogonadotropic hypogonadism, 14.2 versus 4.8 IU/I (p < 0.02).
In plain wordsPeak FSH after diagnostic nafarelin was higher with constitutional growth delay than hypogonadotropic hypogonadism.
Peptide
Nafarelin
Outcome
IncreasePeak FSH diagnostic response by diagnosis
Study
n = 11
Comparator
Hypogonadotropic hypogonadism
Outcome group
Sex hormones and fertility · Endocrine and hormones
Measurements
Mean peak FSH
14.2 IU/I
CGD
Peak FSH dispersion
2.4 IU/I
CGD +/-
Mean peak FSH
4.8 IU/I
HH
Peak FSH dispersion
2 IU/I
HH +/-
P value
< 0.02
CGD vs HH
Source sentences
Summary
Peak FSH released by nafarelin was 14.2 +/- 2.4 IU/I for the CGD group and 4.8 +/- 2.0 IU/I for the HH group (p < 0.02).
2 context sentences(design, population, supporting numbers)
Summary · context
we evaluated six boys (mean age 15 yr 4 m) and five HH patients (mean age 20 yr 4 m).
Summary · context
Each of the patients had blood withdrawn every 15 min during 12 h overnight followed by a single s.c. injection of nafarelin (1 microgram(s)/kg up to 100 microgram(s)), except two HH patients who did not have an overnight study.
In this study, Nafarelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Nafarelin.
Report a problemFND-0888712904
05HumanNot a test of Nafarelin aloneObservational studyActivity measurement
After diagnostic nafarelin, peak testosterone at 24 h was higher with constitutional growth delay than hypogonadotropic hypogonadism, 5.7 versus 0.3 nmol/I.
In plain wordsPeak testosterone after diagnostic nafarelin was higher with constitutional growth delay than hypogonadotropic hypogonadism.
Peptide
Nafarelin
Outcome
IncreasePeak testosterone diagnostic response at 24 hours
Study
n = 11
Comparator
Hypogonadotropic hypogonadism
Outcome group
Sex hormones and fertility · Endocrine and hormones
Measurements
Time to peak testosterone
24 h
following injection
Mean peak testosterone
5.7 nmol/I
CGD
Peak testosterone dispersion
1.7 nmol/I
CGD +/-
Mean peak testosterone
0.3 nmol/I
HH
Peak testosterone dispersion
0.2 nmol/I
HH +/-
P value
< 0.001
CGD vs HH
Source sentences
Summary
Peak T was reached 24 h following nafarelin injection and was 5.7 +/- 1.7 nmol/I for the CGD group and 0.3 +/- 0.2 nmol/I for the HH group (p < 0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
we evaluated six boys (mean age 15 yr 4 m) and five HH patients (mean age 20 yr 4 m).
Summary · context
Each of the patients had blood withdrawn every 15 min during 12 h overnight followed by a single s.c. injection of nafarelin (1 microgram(s)/kg up to 100 microgram(s)), except two HH patients who did not have an overnight study.
In this study, Nafarelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Nafarelin.
Report a problemFND-0888712905

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:36 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.